Read our new paper on elastography: link.springer.com/article/10…

👋 Meet our Genitourinary Section Editor: Georgios Agrotis, MD, PhD Check out our editorial board: sciencedirect.com/journal/eu… 🙏 Thank you for your dedication and for being a valued member of the EJR editorial team.

We’re delighted to announce #ICIS2026! 📍 Belfast, Northern Ireland 🏨 The Europa Hotel 📅 23–25 September Welcome to our incoming President, Prof Anju Sahdev, of St Bart’s, London, who's forming her Scientific Committee. Stay tuned for programme highlights and speaker details!

Magnetic Resonance Imaging–based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review sciencedirect.com/science/ar… Systematic review evaluated the benefit–harm balance of incorporating magnetic resonance imaging (MRI) into #ProstateCancer (PCa) screening as either a first-line test or a second-stage test after PSA >3 ng/ml. Across five first-line and four second-stage studies, MRI strategies were compared for cancer detection, biopsy avoidance, and histological outcomes. First-line MRI identified roughly twice as many clinically significant (GG ≥2) cancers as second-stage MRI but left a higher proportion of men MRI-negative, while second-stage MRI markedly reduced biopsy rates and increased the detection ratio of GG ≥2 versus GG 1 cancers with both targeted and systematic biopsies. Both approaches achieved positive benefit-to-harm ratios (>1), indicating net clinical benefit, though first-line MRI needs further feasibility evaluation and standardisation of MRI interpretation and biopsy protocols is essential for consistent screening quality. @IvoSchootsNL @LondonProstate1 @albers_pa @AsbachP @roodvdb @TobiasNordstrom @ShonitP @ProfPadhani @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

We're thrilled to welcome the new chair of Radiology #ChariteBerlin

Join us for this new ICISi Masterclass in Rectal Cancer MRI which will explore staging, restaging, rad-path, image quality and watch & wait. Register now, this ONLINE course will be delivered over 2 half days: 16th - 17th October 2025, from 8:00am. 🔗 icimagingsociety.org.uk/even…

Less than 2 months till #ICIS2025! With the theme 'Precision Diagnostics: Advancing Oncological Imaging Breakthroughs' this event will cover the latest in molecular imaging, radiomics, AI & next-generation techniques & much more 📍 The Hague 📅 24-26 Sep 🔗icimagingsociety.org.uk

Join us for this brand new ICISi Masterclass in Rectal Cancer MRI which will explore staging, restaging, rad-path, image quality and watch & wait. This course takes place over 2 half days, starting at 8am on Thursday 16th and Friday 17th October 2025. icimagingsociety.org.uk/even…

The UNIQUE MRI - RADS COURSE in 10 interactive practical CASES! Don't miss this essential RADIOLOGICAL Course Special low price! CME credits On-SITE and ONLINE 📅6-7 NOV- Prague/CZ INFO: mri-prague.cz @SERAM_RX @RSNA @myESR @ARRS_Radiology @ESMRMB @ISMRM #radiology

👉🏼 highly recommended!! THE experts

Read about our 2025 teaching courses, free webinars, and much more in the International Cancer Imaging Society December eNewsletter 🎄 mailchi.mp/3823e2b8e983/inte…

Most viewed in the last 7 days from @JAMAOnc: Men with negative multiparametric MRI results avoiding biopsy were not at elevated risk of clinically significant prostate cancer. ja.ma/3BF8usc

Proud to share our @JAMAOnc study validating the oncological safety of MRI-guided biopsy decisions in suspected #ProstateCancer. A true honor to work with @AsbachP @IvoSchootsNL @veerukasi @CashHannes on this 3-year monitoring study. @ChariteBerlin ja.ma/41vdL02

Welcome back in Berlin Martin! Good to have THE prostate focal therapy expert back in town again 🤝

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected #ProstateCancer jamanetwork.com/journals/jam… This cohort study assessed the safety of omitting prostate biopsy (PB) in men with suspected prostate cancer who had negative multiparametric MRI (mpMRI) results. Among 593 men studied, 48% had negative MRI results, and 86% of these men avoided biopsy over a 3-year period with ongoing clinical monitoring. After 3 years, only 4% of men with negative MRI results were diagnosed with clinically significant prostate cancer (csPCa). The findings suggest that prebiopsy MRI has a high negative predictive value, allowing men with negative MRI results to safely avoid PB when they are closely monitored. This approach supports the use of MRI to reduce unnecessary biopsies without compromising cancer detection. @Charlie_Charite @AsbachP @IvoSc @CashHannes

All star team for the joint RSNA/ESR sessions on prostate cancer !! @IvoSchootsNL @AsbachP @KatarzynaMacura @FennessyFiona

ONLY 1 WEEK! For the EXCLUSIVE MRI RADS COURSE in 10 CASES 🔍 ON-SITE & ONLINE 👉Essential for every radiologist 📉Special low price! theoriacongresos.com/school-… #Radiology @SERAM_RX @myESR @SermeMsk @RSNA @_sirm @ESMRMB @ARRS_Radiology

📅 Save the date for ICIS 2025! ICIS President, Prof. Thierry Huisman, warmly invites you to attend his meeting. Our 24th annual teaching course will take place in The Hague Conference Centre, from Wednesday 24 to Friday 26 September.

ONLY 3 weeks! For the UNIQUE MRI RADS COURSE In 10 CASES! A radiologist cannot miss! Low-fare registrations 🔝 On-SITE and ONLINE November 7-8, 2024, Porto/PT INFO: theoriacongresos.com/school-… #Radiology @SERAM_RX @myESR @SermeMsk @RSNA @_sirm @ESMRMB @ARRS_Radiology

"The lack of evidence about the utilization and timing of mpMRI in active surveillance (AS) can potentially lead to over or underutilization of this relatively scarce resource. Defining the optimal imaging interval for mpMRI could improve cost-effectiveness by eliminating unnecessarily frequent mpMRIs for men on AS." - Rebecca A. Campbell et al. #EuropeanRadiology 🔗 buff.ly/3N2BrjZ